Medical Developments International (MVP) AGM 2025 summary

Opening remarks and agenda

• Meeting opened as a hybrid event, enabling both in-person and virtual participation.

• Chair Gordon Naylor announced this is his final AGM, with Mark Fladrich to succeed him in December 2025.

• Quorum confirmed, and meeting procedures, including voting and Q&A protocols, were outlined.

• Five resolutions were scheduled, with business and governance updates preceding formal proceedings.

Financial performance review

• FY 2025 saw an 18% increase in group revenue and a return to modest net profit after tax.

• Positive operating cash flow achieved in the second half of FY 2025.

• Fundraising in FY 2025 enabled targeted investments to support growth strategy.

• Q1 FY 2026 results indicate business is tracking to expectations, with strong Penthrox volumes and improved pricing in Australia.

Board and executive committee updates

• Mark Fladrich and Paul Townsend introduced as new board members, both standing for election.

• Christine Emmanuel-Donnelly and Leon Hoare stood for re-election by rotation.

• CEO Brent MacGregor highlighted robust board-management collaboration and succession planning.